Skip to main content
    K

    Kamada (KMDA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $8.11
    +0.02 (+0.25%)

    Market Cap: $467.05M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Kamada (KMDA) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Kamada (KMDA) is expected to report earnings on Mar 9, 2027. In the quarter ended Sep 30, 2026, Kamada reported EPS of $0.14, above the $0.13 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    41%(16/39)
    Avg Surprise
    -33.69%
    Streak
    2 Q

    Upcoming Estimates

    Reports Mar 9, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.11
    Range$0.09 - $0.14
    6 analysts
    Revenue Consensus
    $52.09M
    Range$45.22M - $57.09M
    6 analysts
    Reports May 11, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.10
    Range$0.10 - $0.10
    1 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.11-9.1%
    60d ago$0.11-9.1%
    30d ago$0.100.0%
    7d ago$0.100.0%
    Current$0.10
    Revenue Consensus
    $161.19M
    Range$161.19M - $161.19M
    1 analysts

    Next Report

    KMDA has an expected report date of Mar 9, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 83.3% above the $0.06 reported for the quarter ended Dec 31, 2025.

    KMDA Earnings Call

    The latest KMDA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, KMDA beat 16, missed 17 and matched 6. Revenue for the quarter ended Sep 30, 2026 was $51.07M, up 8.6% from $47.01M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.14$0.13$0.10 - $0.16+7.69%Beat+55.6%40 up, 1 downNov 9, 2026$51.07M
    Jun 30, 2026$0.16$0.12$0.09 - $0.13+33.33%Beat+23.1%41 up, 1 downAug 12, 2026$54.92M
    Mar 31, 2026$0.07$0.12$0.10 - $0.14-41.67%Miss0.0%41 up, 1 downMay 13, 2026$45.24M
    Dec 31, 2025$0.06$0.10$0.05 - $0.10-40.00%Miss-14.3%41 up, 0 downMar 11, 2026$44.68M
    Sep 30, 2025$0.09$0.09$0.08 - $0.110.00%In line+28.6%41 up, 0 downNov 10, 2025$47.01M
    Jun 30, 2025$0.13$0.09$0.08 - $0.11+44.44%Beat+62.5%42 up, 0 downAug 13, 2025$44.75M
    Mar 31, 2025$0.07$0.07$0.06 - $0.070.00%In line+75.0%40 up, 0 downMay 14, 2025$44.02M
    Dec 31, 2024$0.07$0.05$0.04 - $0.07+31.33%Beat-22.2%30 up, 0 downMar 5, 2025$39.01M
    Sep 30, 2024$0.07$0.07$0.06 - $0.070.00%In line+16.7%30 up, 0 downNov 13, 2024$41.74M
    Jun 30, 2024$0.08$0.06$0.05 - $0.06+33.33%Beat+100.0%30 up, 0 downAug 14, 2024$42.47M
    Mar 31, 2024$0.04$0.07$0.05 - $0.07-42.86%MissN/A20 up, 0 downMay 8, 2024$37.74M
    Dec 31, 2023$0.09$0.05$0.04 - $0.06+80.00%Beat+28.6%20 up, 0 downMar 6, 2024$36.43M
    Sep 30, 2023$0.06$0.02$0.02 - $0.04+200.00%Beat+20.0%20 up, 0 downNov 13, 2023$37.93M
    Jun 30, 2023$0.04$0.03$0.01 - $0.03+33.33%BeatN/A20 up, 0 downAug 16, 2023$37.44M
    Mar 31, 2023-$0.04$0.04$0.01 - $0.04-200.00%MissN/A20 up, 0 downMay 24, 2023$30.71M
    Dec 31, 2022$0.07$0.07$0.04 - $0.090.00%In lineN/A20 up, 0 downMar 15, 2023$45.44M
    Sep 30, 2022$0.05-$0.03-$0.03 - -$0.03+266.67%BeatN/A10 up, 0 downNov 22, 2022$32.22M
    Jun 30, 2022-$0.05-$0.02N/A-150.00%Miss-350.0%N/AN/AAug 17, 2022$23.59M
    Mar 31, 2022-$0.04$0.03N/A-233.33%Miss-180.0%N/AN/AMay 17, 2022$28.09M
    Dec 31, 2021-$0.11-$0.01-$0.02 - $0.02-1000.00%Miss-375.0%20 up, 0 downMar 15, 2022$31.47M
    Sep 30, 2021-$0.02$0.02$0.02 - $0.03-200.00%Miss-113.3%20 up, 0 downNov 22, 2021$23.03M
    Jun 30, 2021$0.02$0.06$0.04 - $0.06-66.67%Miss-75.0%2N/AAug 11, 2021$24.24M
    Mar 31, 2021$0.05$0.07$0.02 - $0.18-28.57%Miss-58.3%3N/AMay 12, 2021$24.90M
    Dec 31, 2020$0.04$0.10$0.04 - $0.10-60.00%Miss-66.7%3N/AFeb 10, 2021$31.54M
    Sep 30, 2020$0.15$0.09$0.03 - $0.09+66.67%Beat+7.1%3N/ANov 11, 2020$35.33M
    Jun 30, 2020$0.08$0.12$0.09 - $0.12-33.33%Miss-46.7%3N/AAug 12, 2020$33.09M
    Mar 31, 2020$0.12$0.05$0.04 - $0.10+140.00%Beat0.0%3N/AMay 18, 2020$33.29M
    Dec 31, 2019$0.12$0.14$0.11 - $0.14-14.29%Miss-73.3%3N/AFeb 12, 2020$32.07M
    Sep 30, 2019$0.14$0.09$0.05 - $0.09+55.56%BeatN/A3N/ANov 13, 2019$33.07M
    Jun 30, 2019$0.15$0.17$0.12 - $0.17-11.76%Miss+7.1%3N/AAug 6, 2019$35.25M
    Mar 31, 2019$0.12$0.01$0.01 - $0.08N/AN/A+300.0%3N/AMay 14, 2019$26.80M
    Dec 31, 2018$0.45$0.19$0.11 - $0.23+136.84%Beat+181.3%3N/AFeb 12, 2019$48.21M
    Sep 30, 2018-$0.06-$0.02N/A-200.00%MissN/AN/AN/ANov 12, 2018$14.97M
    Jun 30, 2018$0.14$0.04N/A+250.00%Beat+7.7%2N/AAug 7, 2018$33.84M
    Mar 31, 2018$0.03$0.04$0.00 - $0.04-25.00%MissN/A3N/AMay 15, 2018$17.44M
    Dec 31, 2017$0.16$0.10$0.06 - $0.10+60.00%BeatN/A2N/AFeb 7, 2018$35.71M
    Sep 30, 2017-$0.01-$0.01N/A0.00%In lineN/A1N/ANov 13, 2017$22.92M
    Jun 30, 2017$0.13$0.13$0.10 - $0.130.00%In lineN/A2N/AAug 1, 2017$32.55M
    Mar 31, 2017-$0.11-$0.02-$0.05 - $0.00-450.00%MissN/A2N/AMay 16, 2017$11.65M
    Dec 31, 2016-$0.05-$0.09N/A+44.44%Beat-266.7%N/AN/AFeb 6, 2017$24.26M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.35, up 34.6% from the year before. It was -$0.15 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.35+34.6%
    Dec 31, 2024$0.26+73.3%
    Dec 31, 2023$0.15+400.0%
    Dec 31, 2022$0.03N/A
    Dec 31, 2021-$0.06-115.4%
    Dec 31, 2020$0.39-26.4%
    Dec 31, 2019$0.53N/A
    Dec 31, 2018$0.56+229.4%
    Dec 31, 2017$0.17N/A
    Dec 31, 2016-$0.15N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,100 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20263,0546
    2026Q2Jun 30, 20263,3876
    2026Q1Mar 31, 20263,0416
    2025Q4Dec 31, 20253,4517
    2025Q3Sep 30, 20253,7626
    2025Q2Jun 30, 20253,1466
    2025Q1Mar 31, 20252,7776
    2024Q3Sep 30, 20242,7675

    2026Q3 Earnings Call

    Opening remarks

    Brian Ritchie Managing Director, LifeSci Advisors Thank you, Operator. This is Brian Ritchie with LifeSci Advisors. Thank you all for participating in today's call. Joining me from Kamada are Amir London, Chief Executive Officer, and Chaime Orlev, Chief Financial Officer. Earlier today, Kamada announced its financial results for the 3 and 9 months ended September 30, 2026. If you have not received this news release, please go to the Investors page of the company's website at kamada.com. Before we begin, I would like to caution that comments made during this conference call by management will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Kamada. I encourage you to review the company's filings with the Securities and Exchange Commission, including, without limitation, the company's Forms 20-F and 6-K, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, Monday, November 9, 2026. Kamada undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call. With that said, it is my pleasure to turn the call over to Amir London, CEO. Amir.

    Amir London CEO Thank you, Brian. My thanks also to our investors and analysts for your interest in Kamada and for participating in today's call. During the third quarter of 2026, we continued with the strong operational and financial performance we demonstrated throughout the year, with double-digit growth in revenues and adjusted EBITDA for both the third quarter and the 9-month reporting period. Based on our excellent performance, we are increasing our 2026 annual guidance, and we are projecting continued double-digit profitable growth during 2027. Total revenues for the 9-month period were a record of $152.2 million, an increase of approximately 12% year-over-year. Adjusted EBITDA was $40.9 million, up 20% year-over-year, and representing a 27% margin of revenues, and net income totaled $21.4 million, up 29% year-over-year. The underlying demand for our products, especially KEDRAB in the U.S. market, as well as VARIZIG and HEPAGAM, continues to expand. We are also pleased to announce another cash dividend of $0.14 per share for a total payment of approximately $8 million to be paid to our shareholders during the fourth quarter of this year. This is in addition to the $24.2 million dividend payments already made earlier this year, bringing the total dividend in 2026 to approximately $32.3 million. Our ability to continue paying dividends while maintaining our strong cash position and continuing to invest in commercial growth is indicative of our excellent financial and operational performance.

    Frequently Asked Questions About KMDA

    When is Kamada's next earnings date?

    Kamada's next earnings report is expected for Mar 9, 2027.

    Did KMDA beat earnings estimates last quarter?

    Yes. Kamada reported EPS of $0.14 for the quarter ended Sep 30, 2026, above the $0.13 estimate, a 7.69% surprise.

    What EPS do analysts expect from KMDA next quarter?

    The consensus EPS estimate for Kamada for the quarter ending Dec 31, 2026 is $0.11 from 6 analysts, with estimates from $0.09 to $0.14.

    How often does KMDA beat earnings estimates?

    Kamada beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +4.39%.